Xvivo Perfusion Ab Stock Current Asset
| XVIPF Stock | USD 41.23 0.77 1.83% |
Xvivo Perfusion AB fundamentals help investors to digest information that contributes to Xvivo Perfusion's financial success or failures. It also enables traders to predict the movement of Xvivo Pink Sheet. The fundamental analysis module provides a way to measure Xvivo Perfusion's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Xvivo Perfusion pink sheet.
Xvivo |
Xvivo Perfusion AB Company Current Asset Analysis
Xvivo Perfusion's Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
| Competition |
In accordance with the recently published financial statements, Xvivo Perfusion AB has a Current Asset of 0.0. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Medical Devices industry. The current asset for all United States stocks is 100.0% higher than that of the company.
Did you try this?
Run FinTech Suite Now
FinTech SuiteUse AI to screen and filter profitable investment opportunities |
| All Next | Launch Module |
Xvivo Fundamentals
| Return On Equity | 0.0136 | |||
| Return On Asset | 0.0057 | |||
| Profit Margin | 0.04 % | |||
| Current Valuation | 536.1 M | |||
| Shares Outstanding | 29.83 M | |||
| Shares Owned By Insiders | 12.25 % | |||
| Shares Owned By Institutions | 54.00 % | |||
| Price To Earning | 166.11 X | |||
| Price To Book | 4.58 X | |||
| Price To Sales | 16.90 X | |||
| Revenue | 258.39 M | |||
| Gross Profit | 296.96 M | |||
| EBITDA | 39.2 M | |||
| Net Income | 8.15 M | |||
| Cash And Equivalents | 22.66 M | |||
| Cash Per Share | 0.86 X | |||
| Debt To Equity | 0 % | |||
| Current Ratio | 6.48 X | |||
| Book Value Per Share | 2.28 X | |||
| Cash Flow From Operations | (12.06 M) | |||
| Earnings Per Share | 0.10 X | |||
| Number Of Employees | 133 | |||
| Beta | 1.97 | |||
| Market Capitalization | 674.8 M | |||
| Total Asset | 1.54 B | |||
| Net Asset | 1.54 B |
About Xvivo Perfusion Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Xvivo Perfusion AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Xvivo Perfusion using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Xvivo Perfusion AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Xvivo Pink Sheet
Xvivo Perfusion financial ratios help investors to determine whether Xvivo Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Xvivo with respect to the benefits of owning Xvivo Perfusion security.